Wedbush Reiterates “Neutral” Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “neutral” rating reaffirmed by investment analysts at Wedbush in a report released on Thursday, MarketBeat.com reports. They presently have a $0.40 price objective on the stock, down from their prior price objective of $7.00. Wedbush’s price objective points to a potential upside of 164.38% from the stock’s current price.

Several other equities analysts also recently commented on the stock. HC Wainwright lowered their price objective on shares of Vor Biopharma from $17.50 to $13.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Oppenheimer reiterated an “outperform” rating and issued a $8.00 price objective on shares of Vor Biopharma in a report on Friday, March 21st. Finally, Stifel Nicolaus reduced their target price on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.06.

Vor Biopharma Stock Down 5.4 %

Shares of NYSE VOR opened at $0.15 on Thursday. The firm’s fifty day moving average is $0.70 and its 200 day moving average is $0.97. Vor Biopharma has a 52 week low of $0.13 and a 52 week high of $1.87. The company has a market cap of $18.89 million, a price-to-earnings ratio of -0.09 and a beta of -0.21.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in VOR. Virtu Financial LLC bought a new position in shares of Vor Biopharma in the 4th quarter worth about $60,000. XTX Topco Ltd purchased a new position in shares of Vor Biopharma during the fourth quarter valued at approximately $80,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Vor Biopharma in the 4th quarter worth approximately $33,000. Lynx1 Capital Management LP purchased a new stake in shares of Vor Biopharma in the 4th quarter worth approximately $707,000. Finally, Northern Trust Corp increased its position in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after buying an additional 44,252 shares in the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.